Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies

[1]  K. Dickstein,et al.  The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators. , 2000, Journal of the American College of Cardiology.

[2]  J. Cleland,et al.  The LIDO, HOPE, MOXCON and WASH studies , 1999 .

[3]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[4]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[5]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[6]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[7]  N Freemantle,et al.  beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.

[8]  A. Philip,et al.  History, definition, and classification of heart failure , 1997 .

[9]  Australia..  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.

[10]  C R Benedict,et al.  Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. , 1996, Circulation.

[11]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[12]  A. Struthers.  Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. , 1996, Journal of cardiac failure.

[13]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[14]  S. Yusuf,et al.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.

[15]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[16]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[17]  J. Laragh.  A decade of angiotensin-converting enzyme (ACE) inhibition. , 1992, The American journal of medicine.

[18]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[19]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[20]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[21]  W. Anderson,et al.  Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. , 1988, Hypertension.

[22]  K. Swedberg,et al.  Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. , 1984, The American journal of cardiology.

[23]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[24]  D. Sharpe,et al.  Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. , 1984, Circulation.

[25]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[26]  J. Staessen,et al.  Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.

[27]  K. Swedberg,et al.  PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE , 1979, The Lancet.

[28]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[29]  E. Braunwald,et al.  CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. , 1965, The American journal of medicine.